“…Second-line treatment involves switching or augmentation of these interventions based on initial patient response ( Kennedy et al, 2016 ; Parikh et al, 2016 ; Park & Zarate, 2019 ). Non-invasive brain stimulation (NIBS) treatments such as transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS) have also been turned to in recent years due to evidence of their ability to modulate cortical activity ( Mutz et al, 2018 ; Nitsche et al, 2009 ; Zugliani et al, 2021 ). Pharmacological, psychotherapeutic, and NIBS interventions have been shown to be effective on their own in some capacity to treat MDD ( Butler et al, 2006 ; Cipriani et al, 2018 ; Cuijpers et al, 2008 ; Fournier et al, 2010 ; Mutz et al, 2018 ; Nitsche et al, 2009 ; Zugliani et al, 2021 ), but not without their own limitations (e.g., treatment resistance, side effects, accessibility, and cost barriers) ( Kennedy et al, 2016 ; Milev et al, 2016 ; Parikh et al, 2016 ; Park & Zarate, 2019 ).…”